ClinicalTrials.gg
CompletedNCT04460651PREPARE-ITUpdated Sep 17, 2021

PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial

A Phase 3 interventional study of Icosapent ethyl (IPE) and Placebo in COVID19, sponsored by Estudios Clínicos Latino América. Completed at 1 site in Argentina. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by Estudios Clínicos Latino América · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,093
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in COVID-19 with a site in Argentina — 6 open to participants now, 7 under way, 5 of them phase 3. COVID-19 · Argentina.

Enrollment
6th of 87
4,093 · median 414
Started
2020
with 69 others
Phase 3
35 of 127
4 open now
Registered
29th of 127
by date

Among the 127 studies in COVID-19 with a site in Argentina, this one is the 6th largest by enrollment of the 87 interventional ones that give a count, is one of 70 that started in 2020, is one of 35 in phase 3, and was the 29th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 127 studies in COVID-19 with a site in Argentina are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in COVID-19 with a site in Argentina, or all of them as a file.
02

Study summary

The PREPARE-IT investigator-initiated trial program is a simple, pragmatic, therapeutic strategy evaluating pure icosapent ethyl (IPE) at initially higher doses intended to reduce infection rates and subsequent morbidity and mortality among subjects at high risk of infection due to COVID-19 (prevention arm), and to reduce the hospitalization rate and complications in patients with a positive diagnosis of COVID-19 (treatment arm).

Read the detailed description

Few vaccines have received emergency authorization providing relative immunity, reducing both transmission and infection rates and subsequent associated morbidity and mortality. However, broad access to vaccines is limited globally, and emergence of COVID-19 viral mutations and vaccine breakthrough cases underscore the need for complementary effective therapies.

To date, there are limited systemic options available for effective treatment from viral-inhibitors, polyclonal antibodies (immunomodulatory drugs) to mitigate the inflammatory cascade and subsequent cytokine storm, and low-dose steroids such as dexamethasone in high-risk patients, which was associated with a reduction in mortality.

Icosapent ethyl (IPE) is a safe, well-tolerated oral therapy proven to be effective in improving outcomes in patients with established cardiovascular disease or diabetes with one or more additional risk factors.

In the context of COVID-19, a recent pilot study on 50 patients on a loading dose of 8g/day for three days, followed by 4g/daily showed a significant improvement in validated patient-reported FLU-PRO score symptoms. A corresponding reduction in a key biomarker of inflammation (hs-CRP) was also detected within the IPE arm at 14 days.

While this pilot study provides the first evidence of an early anti-inflammatory effect of IPE, to confirm these findings, we designed a randomized, placebo-controlled study program investigating IPE with a similar loading dose intended to reduce infection rates and subsequent morbidity and mortality among subjects at high risk of infection from SARS-CoV-2 (prevention arm), and to reduce the hospitalization rate and complications in patients with a positive diagnosis of COVID-19 (treatment arm).

03

Conditions studied

  • COVID19

Browse trials for

Keywords

  • Icosapent ethyl
  • Vascepa
  • Eicosapentaenoic acid ethyl ester
  • Ethyl-EPA
  • AMR101
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

(A) Prevention arm:

Inclusion Criteria:

  1. 18 years of age or older and
  2. any subject that is circulating and exposed to the public

Exclusion Criteria:

  1. Previously diagnosed with COVID-19
  2. Positive pregnancy test at the time of study entry in potentially fertile women
  3. Pregnant or breastfeeding women
  4. Subject who has received one or more doses of any vaccine for Sars-Cov-2 or who is scheduled to be vaccinated within the next 60 days
  5. Unable to provide
  6. Clear to EPA
  7. Known to the study drug
  8. Administration of a drug with anticoagulant effects (antiplatelet agents are allowed)
  9. Hemorrhagic Diathesis

(B) Treatment arm:

Inclusion Criteria:

  1. 40 years of age or older and
  2. Covid 19 diagnosis confirmed with SARS Cov-2 test (RT-PCR) and
  3. No more than 7 days from the onset of symptoms and
  4. Without clear indication for hospitalization (1-2 in the WHO COVID-19 Descriptive Score).

Exclusion Criteria:

  1. Hospitalized patient or with a clear indication of hospitalization for COVID-19
  2. Pregnant or breastfeeding women
  3. Lack of access to adequate means of communication via the web
  4. Unable to provide informed consent
  5. Clear contraindication to EPA
  6. Known hypersensitivity to the study drug
  7. Administration of a drug with anticoagulant effects (antiplatelet agents are allowed)
  8. Hemorrhagic Diathesis

Subjects who fill out the pre-selection form will be evaluated and approved for admission to the clinical trial after confirming their entry criteria

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4,093 participants (actual)

Study arms

  • Active comparator
    Active treatment

    Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.

    Drug: Icosapent ethyl (IPE)

  • Placebo comparator
    Placebo

    Participants in this arm will receive Placebo with the same dose scheme as the active comparator:

    Drug: Placebo

Interventions

  • DrugEicosapentaenoic acid ethyl esterStudies of Eicosapentaenoic acid ethyl esterEicosapentaenoic acid ethyl ester pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in this arm will receive study medication IPE with the following dosage schedule: 8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)

    Also known as: Vascepa®

  • DrugPlacebo

    Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)

06

What researchers measure

Primary outcomes

  1. (A) Prevention Arm: SARS-CoV-2 positivity assesed up to day 60.

    SARS-CoV-2 positive subjects are defined as subjects with positive tests for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies after developing COVID-19 disease at any stage within the follow-up period (including those subjects with or without symptomatic COVID-19 evaluated before the final visit) or those individuals who test positive for SARS-CoV-2 RT-PCR or for SARS-CoV-2 lgG antibodies at the final visit (day 60).

    Time frame: 60 days

  2. (B) Treatment Arm: COVID 19 related hospitalization (indication for hospitalization per the blinded investigator or actual hospitalization) or death assessed up to 28 days

    Time frame: 28 days

Secondary outcomes

  1. (A) Prevention Arm: High-sensitivity C-reactive Protein (mg/dL) change from baseline to day 60 (key secondary outcome)

    Mean change from baseline will be computed

    Time frame: baseline, 60 days

  2. (A) Prevention Arm: Triglycerides (mg/dL) change from baseline to day 60

    Mean change from baseline will be computed

    Time frame: baseline, 60 days

  3. (A) Prevention Arm: FLU-PRO SCORE change from baseline to day 60 in a subset of subjects

    Mean change from baseline will be computed

    Time frame: baseline, 60 days

  4. (B) Treatment Arm: COVID 19 related hospitalization or death assessed up to 28 days (key secondary outcome)

    Time frame: 28 days

  5. (B) Treatment Arm: Alive and out of the hospital at 28 days.

    Time frame: 28 days

  6. (B) Treatment Arm: In hospital length of stay assessed up to 28 days

    Time frame: 28 days

  7. (B) Treatment Arm: New requirement of mechanical ventilation assed up to 28 days.

    Time frame: 28 days

  8. (B) Treatment Arm: Total events: non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), until day 28.

    Time frame: 28 days

  9. (B) Treatment Arm: Total mortality assessed up to 28 days

    Time frame: 28 days

  10. (B) Treatment Arm: FLU-PRO SCORE change from baseline at 28 days

    Time frame: (B) Treatment Arm:

07

Study locations

1 site
  • Instituto de Investigaciones Clínicas - Rosario
    Rosario, Santa Fe 2000, Argentina
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Aug 2021, 12 months.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 12 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2020
First posted
Jul 7, 2020
StartActual
Aug 14, 2020
Primary completionActual
Aug 30, 2021
CompletionActual
Aug 30, 2021
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04460651
Lead sponsor
Estudios Clínicos Latino América
Collaborators
Amarin Pharma Inc.
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Aug 14, 2020
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Last update
Sep 17, 2021

Study contacts

Rafael Diaz, MD
principal investigator · ECLA- Estudios Clínicos Latino América

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eicosapentaenoic acid ethyl ester

Start the discussion